Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.

CONTEXT In June 2006, the Food and Drug Administration licensed the quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine (qHPV) in the United States for use in females aged 9 to 26 years; the Advisory Committee on Immunization Practices then recommended qHPV for routine vaccination of girls aged 11 to 12 years. OBJECTIVE To summarize reports to the Vaccine Adverse Event Reporting System (VAERS) following receipt of qHPV. DESIGN, SETTING, AND PARTICIPANTS Review and describe adverse events following immunization (AEFIs) reported to VAERS, a national, voluntary, passive surveillance system, from June 1, 2006, through December 31, 2008. Additional analyses were performed for some AEFIs in prelicensure trials, those of unusual severity, or those that had received public attention. Statistical data mining, including proportional reporting ratios (PRRs) and empirical Bayesian geometric mean methods, were used to detect disproportionality in reporting. MAIN OUTCOME MEASURES Numbers of reported AEFIs, reporting rates (reports per 100,000 doses of distributed vaccine or per person-years at risk), and comparisons with expected background rates. RESULTS VAERS received 12 424 reports of AEFIs following qHPV distribution, a rate of 53.9 reports per 100,000 doses distributed. A total of 772 reports (6.2% of all reports) described serious AEFIs, including 32 reports of death. The reporting rates per 100,000 qHPV doses distributed were 8.2 for syncope; 7.5 for local site reactions; 6.8 for dizziness; 5.0 for nausea; 4.1 for headache; 3.1 for hypersensitivity reactions; 2.6 for urticaria; 0.2 for venous thromboembolic events, autoimmune disorders, and Guillain-Barré syndrome; 0.1 for anaphylaxis and death; 0.04 for transverse myelitis and pancreatitis; and 0.009 for motor neuron disease. Disproportional reporting of syncope and venous thromboembolic events was noted with data mining methods. CONCLUSIONS Most of the AEFI rates were not greater than the background rates compared with other vaccines, but there was disproportional reporting of syncope and venous thromboembolic events. The significance of these findings must be tempered with the limitations (possible underreporting) of a passive reporting system.

[1]  Stephen Evans,et al.  Statistical Methods of Signal Detection , 2002 .

[2]  K. Ault.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials , 2007, The Lancet.

[3]  Robert T. Chen,et al.  Morbidity and Mortality Weekly Report , 2002 .

[4]  S. Ashwal,et al.  Venipuncture fits: a form of reflex anoxic seizure. , 1983, Pediatrics.

[5]  X. Castellsagué,et al.  Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women , 2006, Pediatrics.

[6]  U. Bauer,et al.  [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.

[7]  R. Holman,et al.  Guillain‐Barré syndrome: Its epidemiology and associations with influenza vaccination , 1981, Annals of neurology.

[8]  F. X. Bosch,et al.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.

[9]  Robert T. Chen,et al.  Active Surveillance of Vaccine Safety: A System to Detect Early Signs of Adverse Events , 2005, Epidemiology.

[10]  M. Braun,et al.  Fatal syncope-related fall after immunization. , 2005, Archives of pediatrics & adolescent medicine.

[11]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[12]  R. O’Neill,et al.  Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.

[13]  Adverse reactions to non-steroidal antiinflammatory drugs , 1983 .

[14]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[15]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[16]  W. DuMouchel,et al.  Novel Statistical Tools for Monitoring the Safety of Marketed Drugs , 2007, Clinical pharmacology and therapeutics.

[17]  Andrew T. Kroger,et al.  Syncope after vaccination--United States, January 2005-July 2007. , 2008, MMWR. Morbidity and mortality weekly report.

[18]  Benjamin Schwartz,et al.  General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[19]  S. Deitcher,et al.  Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. , 2004, Archives of internal medicine.

[20]  Jan Bonhoeffer,et al.  Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. , 2007, Vaccine.

[21]  Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006. , 2006, MMWR. Morbidity and mortality weekly report.

[22]  J. Kleinstein.  Active and Passive Immunization. , 1938, California and western medicine.

[23]  Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. , 2006, MMWR. Morbidity and mortality weekly report.

[24]  Robert T. Chen,et al.  Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. , 2004, The Pediatric infectious disease journal.

[25]  C. Lai,et al.  Convulsive syncope in blood donors , 1982, Annals of neurology.

[26]  John W. Glasser,et al.  Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. , 1997, Pediatrics.

[27]  J A Bryan,et al.  Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. , 1979, American journal of epidemiology.

[28]  Intussusception among recipients of rotavirus vaccine--United States, 1998-1999. , 1999, MMWR. Morbidity and mortality weekly report.

[29]  S. Ellenberg,et al.  Syncope after immunization. , 1997, Archives of pediatrics & adolescent medicine.

[30]  S. Cochi,et al.  The Vaccine Adverse Event Reporting System (VAERS). , 1994, Vaccine.

[31]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[32]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.